Mesoblast (ASX: MSB) has provided new analyses from the DREAM-HF Phase III trial showing that the greatest treatment benefit from rexlemestrocel-L is in heart failure and low ejection fraction (HFrEF) patients with diabetes and/or ischemia, who are at high-risk of cardiovascular mortality, heart attacks or strokes.
In recent guidance to the Australian allogeneic cell therapy company, the US Food and Drug Administration (FDA) confirmed that reduction in incidence of cardiovascular mortality or irreversible morbidity is a clinically meaningful acceptable endpoint in patients with chronic HFrEF.
The agency encouraged Mesoblast to identify the highest-risk group with greatest likelihood of beneficial response to intervention with rexlemestrocel-L in the DREAM-HF Phase III trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze